Secures first tDCS solution supply deal with top-tier general hospital following June’s announcement of innovative 안전한 바카라사이트 산타카지노 technology
[by Ji, Yong Jun] 안전한 바카라사이트 산타카지노, a company specializing in artificial intelligence (AI) technologies for the diagnosis and treatment of brain disease, announced on November 27 that it has provided its AI-based personalized transcranial direct current stimulation (tDCS) solution to Samsung Medical Center.
This product supply contract represents the first time Neurophet's personalized tDCS solution, designated as an ‘Innovative Medical Technology,’ has been supplied to a tertiary hospital in Korea. The company expects the agreement to serve as a meaningful reference point for expanding adoption across domestic medical institutions going forward.
The personalized tDCS solution received its designation as an innovative medical technology in April for its application in improving finger motor function in stroke patients experiencing finger paralysis. The system comprises ‘Neurophet tES LAB,’ an imaging-based treatment planning software for brain electrical stimulation, and ‘Neurophet innk,’ a transcranial electrical stimulation (tES) device.
Innovative 안전한 바카라사이트 산타카지노 technology refers to technologies deemed to have verified safety and potential clinical utility and that may be used in 안전한 바카라사이트 산타카지노 practice if they meet the criteria established by the Minister of Health and Welfare, including the permitted duration of use, intended purpose, and eligible patient groups.
The solution conducts a detailed analysis of a patient's brain MRI (magnetic resonance imaging) using 안전한 바카라사이트 산타카지노 tES LAB, determines the optimal site and method for stimulation, and applies non-invasive electrical stimulation to the affected region through 안전한 바카라사이트 산타카지노 innk. It is specifically used to aid recovery from finger motor paralysis in stroke patients and is administered in conjunction with rehabilitation therapy.
"It is encouraging that our discussions for the introduction of tDCS solutions with Samsung Medical Center, one of Korea’s leading medical institutions, have so quickly resulted in a supply contract. Based on this milestone, we intend to actively expand product deployment across all domestic medical institutions," remarked Jake Junkil Been, co-CEO of Neurophet.
Conversely, the personalized 안전한 바카라사이트 산타카지노 solution became available for clinical use on July 1, with clinical trials scheduled to continue through June 30, 2028. Once nursing care benefits are established in the future, they may be claimed either as non-covered or covered services.